Modality
siRNA
MOA
MDM2i
Target
SOS1
Pathway
Apoptosis
HNSCCHemophilia APBC
Development Pipeline
Preclinical
~May 2020
→ ~Aug 2021
Phase 1
~Nov 2021
→ ~Feb 2023
Phase 2
May 2023
→ Nov 2031
Phase 2Current
NCT03659567
1,525 pts·Hemophilia A
2024-02→2031-03·Terminated
NCT03518009
1,387 pts·HNSCC
2023-05→2031-11·Active
2,912 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2031-03-165.0y awayPh3 Readout· Hemophilia A
2031-11-075.6y awayPh3 Readout· HNSCC
Trial Timeline
Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
P2/3
Active
P2/3
Termina…
Catalysts
Ph3 Readout
2031-03-16 · 5.0y away
Hemophilia A
Ph3 Readout
2031-11-07 · 5.6y away
HNSCC
ActiveTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03659567 | Phase 2/3 | Hemophilia A | Terminated | 1525 | EASI-75 |
| NCT03518009 | Phase 2/3 | HNSCC | Active | 1387 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Terarelsin | AbbVie | Preclinical | SOS1 | |
| Ribofutibatinib | AstraZeneca | Phase 2/3 | SOS1 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| Rimasertib | Exelixis | Phase 3 | B7-H3 |